A huge problem in treating and preventing infection are newly-emerged multidrug-resistant pathogens. These pathogens are affecting an increasing range of infections caused by bacteria, parasites, viruses and fungi. As such, research finding novel antimicrobials and novel approaches to develop them is a pressing need, making it a perfect field for repurposing. The organoselenium clinical molecule Ebselen has been tested against clinical multidrug-resistant Gram-positive pathogens (these pathogens can cause staph-related diseases, scarlet fever, pneumonia and inflammation). Research demonstrates that Ebselen can be potentially used to treat such bacterial infections alone or in combination with other antibiotics. The compound should be further clinically evaluated to determine maximum effectiveness.
To read the research, follow this link.